Novo Nordisk’s Wegovy and copyright, both of those driven by semaglutide, have revolutionized obesity cure via unprecedented weight loss final results.In Oct 2024, Novo Nordisk revealed a examine on scientific journal Mother nature about a novel glucose-delicate insulin NNC2215 that will lower the potential risk of hypoglycemia in animal designs.